Literature DB >> 665309

Changes in plasma volume and extracellular fluid volume and after addition of hydralazine to propranolol treatment in patients with hypertension.

H Ibsen, K Rasmussen, H A Jensen, A Leth.   

Abstract

In 16 patients with hypertension, BP could not be controlled satisfactorily by treatment with propranolol alone (mean dosage 325 mg/day). Plasma volume (PV) (T-1824) and extracellular fluid volume (ECV) (82Br-distribution space) were determined in these patients before and after the addition of hydralazine for three months (mean dosage 135 mg/day). After the addition of hydralazine, PV and ECV increased significantly, by 9% and 3%, respectively. Systolic and diastolic BPs decreased, by 15% and 13%. The mechanisms inducing fluid retention during treatment with hydralazine and the clinical significance of the problem are discussed. It is concluded that the addition of a diuretic to propranolol-hydralazine treatment is often well indicated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 665309     DOI: 10.1111/j.0954-6820.1978.tb14899.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  9 in total

1.  Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

2.  Effect of oral labetalol on plasma catecholamines, renin and aldosterone in patients with severe arterial hypertension.

Authors:  H J Kornerup; E B Pedersen; N J Christensen; A Pedersen; G Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1979-11       Impact factor: 2.953

3.  Long-term therapy of arterial hypertension with nifedipine given alone or in combination with a beta-adrenoceptor blocking agent.

Authors:  S E Husted; H K Nielsen; C K Christensen; O Lederballe Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy.

Authors:  F H Leenen; R J Burns; M G Myers; D Frankel
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

5.  The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group.

Authors:  H Ibsen; B Westberg
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

6.  Pinacidil, a new vasodilator: pharmacokinetics and pharmacodynamics of a new retarded release tablet in essential hypertension.

Authors:  J E Carlsen; T Kardel; H A Jensen; M Tangø; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Effect of nifedipine on plasma renin, aldosterone and catecholamines in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen; N J Christensen; H J Kornerup; E B Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1979-05-21       Impact factor: 2.953

8.  Renal effects of pinacidil in hypertensive patients on chronic beta-blocker therapy.

Authors:  L R Krusell; C K Christensen; O Lederballe Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Comparison of indapamide and hydrochlorothiazide plus amiloride as a third drug in the treatment of arterial hypertension.

Authors:  L Poulsen; M Friberg; I Noer; L Krusell; O L Pedersen
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.